Biolyst › AMRXAmneal Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
No upcoming catalysts are currently on record for AMRX. Past events are listed below.
Cash runway is approximately 14.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 9 concluded trials, 100% reached completion rather than being terminated or withdrawn.
Upcoming catalysts
Nothing scheduled.
Track AMRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open AMRX in the tracker
Recent history
Date Event Type Phase
August 10, 2026
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure Corporate
—
August 3, 2026
8-K filed: Material agreement Corporate
—
July 30, 2026
Quarterly results filed (8-K) Earnings
—
May 7, 2026
Quarterly results filed (8-K) Earnings
—
April 22, 2026
Quarterly results filed (8-K) Earnings
—
February 27, 2026
Quarterly results filed (8-K) Earnings
—
February 3, 2026
8-K filed: Material agreement Corporate
—
January 28, 2026
8-K filed: Other event Filing
—
January 13, 2026
Quarterly results filed (8-K) Earnings
—
October 30, 2025
Quarterly results filed (8-K) Earnings
—
August 5, 2025
Quarterly results filed (8-K) Earnings
—
August 1, 2025
8-K filed: Material agreement Corporate
—
July 24, 2025
8-K filed: Other event Filing
—
July 21, 2025
Quarterly results filed (8-K) Earnings
—
July 21, 2025
8-K filed: Other event Filing
—
May 2, 2025
Quarterly results filed (8-K) Earnings
—
December 8, 2024
SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females Trial Milestone
Phase 1
December 15, 2022
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes. Trial Milestone
Phase 3
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.